The document summarizes guidelines from the National Institute for Health and Clinical Excellence (NICE) on the use of continuous subcutaneous insulin infusion (CSII or insulin pump therapy) for the treatment of diabetes mellitus. Key points include: 1) CSII therapy is recommended for adults and children 12 years and older with type 1 diabetes who meet specific criteria regarding glycemic control and hypoglycemic episodes. 2) CSII therapy may be considered for children under 12 with type 1 diabetes under special circumstances. 3) Initiation of CSII therapy should only be done by a trained specialist team and continued use requires sustained improvement in glycemic control.